Compare · ALZN vs ANVS
ALZN vs ANVS
Side-by-side comparison of Alzamend Neuro Inc. (ALZN) and Annovis Bio Inc. (ANVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALZN and ANVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ANVS is the larger of the two at $45.7M, about 8.4x ALZN ($5.5M).
- ANVS has been more active in the news (17 items in the past 4 weeks vs 3 for ALZN).
- ANVS has more recent analyst coverage (5 ratings vs 1 for ALZN).
- Company
- Alzamend Neuro Inc.
- Annovis Bio Inc.
- Price
- -
- -
- Market cap
- $5.5M
- $45.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2020
- News (4w)
- 3
- 17
- Recent ratings
- 1
- 5
Alzamend Neuro Inc.
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Annovis Bio Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Latest ALZN
- SEC Form S-3 filed by Alzamend Neuro Inc.
- Alzamend Neuro Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Amendment: Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form RW filed by Alzamend Neuro Inc.
- Alzamend Neuro Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
- SEC Form 10-Q filed by Alzamend Neuro Inc.
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Director Ault Milton C Iii sold $3,116 worth of shares (2,000 units at $1.56), closing all direct ownership in the company (SEC Form 4)
Latest ANVS
- Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study
- SEC Form 10-Q filed by Annovis Bio Inc.
- Annovis Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
- Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
- Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
- Director Hoffman Michael B bought $5,000,000 worth of shares (5,000,000 units at $1.00), increasing direct ownership by 149% to 8,364,883 units (SEC Form 4)
- Annovis Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 424B5 filed by Annovis Bio Inc.
- Annovis Announces Pricing of $21.0 Million Public Offering